Cite
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.
MLA
Moreau-Bachelard, Camille, et al. “Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.” Cancers, vol. 12, no. 12, Dec. 2020, p. 3725. EBSCOhost, https://doi.org/10.3390/cancers12123725.
APA
Moreau-Bachelard, C., Campion, L., Robert, M., Kerdraon, O., Renaudeau, C., Aumont, M., Classe, J.-M., Campone, M., & Frénel, J.-S. (2020). Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. Cancers, 12(12), 3725. https://doi.org/10.3390/cancers12123725
Chicago
Moreau-Bachelard, Camille, Loïc Campion, Marie Robert, Olivier Kerdraon, Céline Renaudeau, Maud Aumont, Jean-Marc Classe, Mario Campone, and Jean-Sébastien Frénel. 2020. “Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.” Cancers 12 (12): 3725. doi:10.3390/cancers12123725.